Polyrizon Sees 370.46% Surge in Search Activity

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:Telescope Innovations, 4,976.92% surge in interestPolyrizon, 370.46% surge in interestPipeline and key clinical candidates for these companies:Telescope Innovationsis a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality.Polyrizonis a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon's proprietary Capture and Contain T, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a "biological mask" with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs.Recent news on these stocks:January 5Polyrizon announced "positive" results from a new in-vitro pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose, an accepted and standard comparator used in nasal barrier products. "These results reinforce our belief that PL-14 can form an effective intranasal hydrogel barrier capable of reducing allergen exposure to nasal tissue. Importantly, this study benchmarked PL-14 against HPMC, an accepted comparator, and demonstrated statistically significant reduction in allergen transfer at all evaluated time points. From an R&D standpoint, we believe that this is an important confirmation of the performance of the PL-14 formulation using a rigorous quantitative permeation model. The data support continued advancement of PL-14 as a potential preventive approach for allergic rhinitis by reducing allergen penetration through a synthetic surface," said Tomer Izraeli, CEO of Polyrizon.Hear more from InvestingChannel by signing up for.About "Biotech Alert"The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel's online financial news media ecosystem.This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.